Sjögren's Syndrome Highlights
This year’s research focus on Sjogren’s syndrome was dominated by studies on the pathogenesis of the disease utilizing mouse models as well as human tissues. Further studies reported on outcomes of therapy with Rituximab, a monoclonal anti-CD20 antibody, that has already successfully been applied in other systemic autoimmune diseases. Finally, several studies reported on the significance of fatigue for patients with Sjogren’s syndrome, psychological impacts as well as possible therapeutic approaches. This years’ abstracts did not address novel aspects of early diagnosis and measurements of disease activity in Sjogren’s syndrome.
- Abstract 1083: New Murine Model for Sjogren's Syndrome Established by M3 Muscarinic Acetylcholine Receptor Immunization
- Abstract 1080: Constricture of the Excretory Duct in Parotid Salivary Glands of a Mouse Model of Sjögren’s Syndrome that Exhibits Decreased Salivary Flow
- Abstract 1360: Reovirus-1 (a dsRNA Virus) and Poly (I:C) Induce High Expression of BAFF mRNA and Protein by Salivary Epithelial Cells Through TLR3 / Type I-interferon - Dependant and - Independent Pathways
- Abstract 1102: Rituximab Therapy for Primary Sjögren's Syndrome (pSS): An Open-Label Trial
- Abstract 1090: Clinical and Immunological Expression of the Epidemiologic Subsets of Primary Sjögren’s Syndrome. Multicenter Study of 1000 Patients
- Abstract 1359: Interferon-Alpha Induces Up-Regulation and Nuclear Tranlocation of the Ro52 Autoantigen
- Abstract 1079: Expression of Proteasomal Immunosubunit Beta1i (LMP2) is Suppressed in Inflammatory Infiltrates of Minor Salivary Glands in Sjögren´s Syndrome
